Archives
VX-745: Selective p38α MAPK Inhibitor for Inflammation an...
VX-745: Selective p38α MAPK Inhibitor for Inflammation and Disease Models
Executive Summary: VX-745 is a potent, ATP-competitive inhibitor of the p38α mitogen-activated protein kinase (MAPK) with an IC50 of 10 nM, displaying >20-fold selectivity over the p38β isoform (IC50 220 nM) (APExBIO). It blocks phosphorylation events central to inflammatory cytokine production, notably IL-1β and TNF-α, in human immune cell models (Qiao et al., 2024). VX-745 has demonstrated efficacy in mouse models of collagen-induced arthritis, reducing joint inflammation and bone erosion. The compound's selectivity and dual-action mechanism have been structurally validated, rationalizing its use in complex disease modeling (Qiao et al., 2024). VX-745 is supplied by APExBIO for research use only and is not intended for clinical or diagnostic applications.
Biological Rationale
The p38α MAPK pathway regulates cellular responses to stress, inflammation, and differentiation. Dysregulation is implicated in autoimmune conditions, chronic inflammation, and cancer (Qiao et al., 2024). p38α is the dominant isoform mediating inflammatory cytokine production in monocytes, macrophages, and stromal cells. Targeted inhibition of p38α, rather than pan-p38 blockade, reduces off-target effects and preserves key homeostatic processes (Related: Mechanistic insights, which this article extends by providing updated structural benchmarks and workflow parameters). VX-745's selectivity for p38α MAPK enables precise dissection of inflammation-related signaling without broadly suppressing MAPK functions.
Mechanism of Action of VX-745
VX-745 binds to the ATP-binding pocket of p38α MAPK, stabilizing an inactive conformation of the activation loop. This conformational stabilization increases accessibility for phosphatases (e.g., WIP1), accelerating dephosphorylation of the activation loop's phospho-threonine (Qiao et al., 2024). This dual-action — direct kinase inhibition and enhanced phosphatase activity — leads to potent, sustained suppression of downstream p38α signaling. As a result, phosphorylation of substrates such as MAPKAPK2 and the transcriptional machinery responsible for IL-1β, TNF-α, and IL-6 production is reduced. In cell-based models, this translates to dose-dependent inhibition of pro-inflammatory cytokine secretion. VX-745 does not inhibit p38β MAPK at concentrations below 200 nM, minimizing non-specific effects (APExBIO).
Evidence & Benchmarks
- VX-745 inhibits human p38α MAPK with an IC50 of 10 nM, and p38β MAPK with an IC50 of 220 nM, demonstrating >20-fold selectivity (APExBIO).
- In peripheral blood mononuclear cells, VX-745 suppresses IL-1β and TNF-α secretion with nanomolar potency (Qiao et al., 2024).
- VX-745 blocks p38 signaling in human dermal fibroblasts and rescues aging-related phenotypes in Werner syndrome cell models (see also, benchmark applications—this article updates the mechanistic model with recent dual-action findings).
- In bone marrow stromal cells (BMSCs), VX-745 inhibits IL-6 and VEGF secretion and blocks TNF-α-induced IL-6 upregulation without cytotoxicity at ≤20 μM (APExBIO).
- In a murine collagen-induced arthritis model, daily dosing of VX-745 reduced joint inflammation and protected against cartilage and bone erosion (Qiao et al., 2024).
- Structural studies confirm VX-745-induced activation loop flipping, facilitating phosphatase-mediated dephosphorylation and inactivation of p38α (Qiao et al., 2024, Fig. 3).
Applications, Limits & Misconceptions
Applications:
- Inflammation research: VX-745 offers precise inhibition for studies on cytokine signaling, stress responses, and innate immunity.
- Multiple myeloma research: Inhibits cell adhesion-mediated IL-6 production and myeloma cell proliferation in BMSC co-culture models (Related: Deeper biological insights; this article details new dual-action mechanisms).
- Aging models: Used to dissect MAPK-dependent pathways in premature aging syndromes (e.g., Werner syndrome).
- Arthritis models: Demonstrated efficacy in reducing joint inflammation and tissue damage in murine CIA models.
Common Pitfalls or Misconceptions
- VX-745 is not a pan-p38 inhibitor; its selectivity profile does not extend to p38γ or p38δ isoforms.
- It is not suitable for clinical or diagnostic use; research-use only designation is strictly enforced (APExBIO).
- It does not inhibit unrelated kinases or phosphatases at standard research concentrations.
- Solubility: VX-745 is not soluble in water; improper vehicle choice may result in precipitation or loss of potency.
- Long-term solution storage is not recommended; activity may decrease over time even at -20°C.
Workflow Integration & Parameters
VX-745 (SKU A8686) is supplied as a solid. The recommended storage is at -20°C in a desiccated environment. For stock solutions, dissolve in DMSO at ≥21.8 mg/mL or in ethanol at ≥2.1 mg/mL with gentle warming and ultrasonic treatment. The compound is insoluble in water. Working concentrations typically range from 60 nM to 20 μM, with incubation times up to 48 hours depending on cell type and endpoint. For cytokine assays, pre-incubate cells with VX-745 for 30–60 minutes before stimulation. Solution stability is limited; prepare fresh aliquots for each experiment. For detailed scenario-based workflow optimization, refer to this scenario-driven guide—this article clarifies dual-action benchmarks and structural validation.
Conclusion & Outlook
VX-745 is a validated, highly selective p38α MAPK inhibitor with robust anti-inflammatory properties and a unique dual mechanism of action. It enables precise dissection of p38α-dependent pathways in inflammation, aging, and cancer research. The product, distributed by APExBIO, is backed by structural, biochemical, and in vivo benchmarks. Future research may expand its utility in translational studies, provided its use remains within research-only guidelines. For comprehensive details and ordering, refer to the VX-745 product page.